Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas

Author(s): Marc Giry-Laterriere, Andreia V. Pinho, Nils Eling, Lorraine Chantrill and Ilse Rooman

Volume 15, Issue 6, 2015

Page: [463 - 468] Pages: 6

DOI: 10.2174/1568009615666150512102957

Price: $65

Abstract

Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.

Keywords: Chemotherapy, Deleted in breast cancer 1, genomic, mutation, pancreas, personalized medicine, Sirtuin 1.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy